Establishment of a risk model correlated with metabolism based on RNA-binding proteins associated with cell pyroptosis in acute myeloid leukemia

Bin, Ting; Lin, Chao-Shun; Liu, Fang-jie; Wang, Ying; Xu, Xiaodong; Lin, Dongjun; Tang, Jing; Lü, Bo

doi:10.3389/fonc.2022.1059978

Cited by 4 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was consistent with our study, which demonstrated that being male was a protective factor for both PFS and OS in Chinese AML patients. In addition, Bin et al ( 21 ) showed that age served as an independent prognostic factor to predict the 1-, 3-, and 5-year survival of AML patients, which was consistent with our study.…”

Section: Discussionsupporting

confidence: 93%

The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients

Wang

Wei

et al. 2023

Front. Med.

View full text Add to dashboard Cite

ObjectiveDiagnosis classification and risk stratification are crucial in the prognosis prediction and treatment selection of acute myeloid leukemia (AML). Here, we used a database of 536 AML patients to compare the 4th and 5th WHO classifications and the 2017 and 2022 versions of ELN guidance.MethodsAML patients were classified according to the 4th and 5th WHO classifications, as well as the 2017 and 2022 versions of the European LeukemiaNet (ELN) guidance. Kaplan–Meier curves with log-rank tests were used for survival analysis.ResultsThe biggest change was that 25 (5.2%), 8 (1.6%), and 1 (0.2%) patients in the AML, not otherwise specified (NOS) group according to the 4th WHO classification, were re-classified into the AML-MR (myelodysplasia-related), KMT2A rearrangement, and NUP98 rearrangement subgroups based on the 5th WHO classification. Referring to the ELN guidance, 16 patients in the favorable group, six patients in the adverse group, and 13 patients in the intermediate group based on the 2017 ELN guidance were re-classified to the intermediate and adverse groups based on the 2022 ELN guidance. Regrettably, the Kaplan–Meier curves showed that the survival of intermediate and adverse groups could not be distinguished well according to either the 2017 or 2022 ELN guidance. To this end, we constructed a risk model for Chinese AML patients, in which the clinical information (age and gender), gene mutations (NPM1, RUNX1, SH2B3, and TP53), and fusions (CBFB::MYH11 and RUNX1::RUNX1T1) were included, and our model could help divide the patients into favorable, intermediate, and adverse groups.ConclusionThese results affirmed the clinical value of both WHO and ELN, but a more suitable prognosis model should be established in Chinese cohorts, such as the models we proposed.

show abstract

Section: Discussionsupporting

confidence: 93%

The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients

Wang

Wei

et al. 2023

Front. Med.

View full text Add to dashboard Cite

show abstract

Ningalins, Pyrrole‐Bearing Metabolites Isolated from Didemnum spp. Synthesis and MDR‐Reversion Activity in Cancer Therapy

Segura‐Quezada,

Hernández‐Velázquez,

Corrales‐Escobosa

et al. 2024

Chemistry & Biodiversity

View full text Add to dashboard Cite

Multi‐Drug Resistance (MDR) is one of the most frequent problems observed in the course of cancer chemotherapy. Cells under treatment, tend to develop survival mechanisms to drug‐action thus generating drug‐resistance. One of the most important mechanism to get it is the over expression of P‐gp glycoprotein, which acts as an efflux‐pump releasing the drug outside of the cancer cell. A strategy for a succesfull treatment consists in the co‐administration of one compound that acts against P‐gp and another which acts against the cell during chemotherapy. Ningalins are pyrrole‐containing naturally occurring compounds isolated mainly from the marine tunicate Didemnum spp and also they are some of the top reversing agents in MDR treatment acting on P‐gp. Considering the relevance displayed for some of these isolated alkaloids or their core as a drug for co‐administration in cancer therapy, all the total synthesis described to date for the members of ningalins family are reviewed herein.

show abstract

Post‐Transcriptional Regulation of Rab7a in Lysosomal Positioning and Drug Resistance in Nutrient‐Limited Cancer Cells

Güleç Taşkıran,

Hüsnügil,

Soltani

et al. 2024

Traffic

View full text Add to dashboard Cite

Limited nutrient availability in the tumor microenvironment can cause the rewiring of signaling and metabolic networks to confer cancer cells with survival advantages. We show here that the limitation of glucose, glutamine and serum from the culture medium resulted in the survival of a population of cancer cells with high viability and capacity to form tumors in vivo. These cells also displayed a remarkable increase in the abundance and size of lysosomes. Moreover, lysosomes were located mainly in the perinuclear region in nutrient‐limited cells; this translocation was mediated by a rapid post‐transcriptional increase in the key endolysosomal trafficking protein Rab7a. The acidic lysosomes in nutrient‐limited cells could trap weakly basic drugs such as doxorubicin, mediating resistance of the cells to the drug, which could be partially reversed with the lysosomal inhibitor bafilomycin A1. An in vivo chorioallantoic membrane (CAM) assay indicated a remarkable decrease in microtumor volume when nutrient‐limited cells were treated with 5‐Fluorouracil (5‐FU) and bafilomycin A1 compared to cells treated with either agent alone. Overall, our data indicate the activation of complementary pathways with nutrient limitation that can enable cancer cells to survive, proliferate and acquire drug resistance.

show abstract

Establishment of a risk model correlated with metabolism based on RNA-binding proteins associated with cell pyroptosis in acute myeloid leukemia

Cited by 4 publications

References 28 publications

The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients

The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients

Ningalins, Pyrrole‐Bearing Metabolites Isolated from Didemnum spp. Synthesis and MDR‐Reversion Activity in Cancer Therapy

Post‐Transcriptional Regulation of Rab7a in Lysosomal Positioning and Drug Resistance in Nutrient‐Limited Cancer Cells

Contact Info

Product

Resources

About